The county joins municipalities across the country suing Eli Lilly, CVS Caremark, and others for sky-high prices.

The market reaction came as Trump signed a wide-ranging executive order aimed at slashing prescription drug prices in the US.

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...

Also Read: Eli Lilly Stock Offers Buying Opportunity For Goldman Sachs. Concerns Over CVS Setback Are Overblown, Analysts Say The collaboration focuses on discovering and developing RNA-editing ...

Shares of Eli Lilly plunged 11% on Thursday. But several Wall Street analysts said the selloff was overblown. "In our view, the Novo/CVS deal does not represent the beginning of an obesity ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

CVS Caremark decided to stop offering Zepbound ... The study involved a large clinical trial comparing the drugs that was funded by Eli Lilly, the maker of Zepbound. Earlier research not financed ...